We next aimed to mimic the clinical features of pediatric patients with MLL-r ALL treated with small-molecule menin inhibitors, which have shown exceptional efficacy in preclinical models, supporting their progress to clinical trials [20,21,22]. This evidence concerns the gene KMT2A and acute lymphoblastic leukemia.